Publications by authors named "F Lebel"
Article Synopsis
- ERBB2 or HER2 alterations occur in 2% to 5% of non-small cell lung cancers (NSCLC), primarily as exon 20 insertion mutations, prompting a study on the oral drug poziotinib in treatment-naive patients with these mutations.
- The ZENITH20-C4 trial involved 80 patients receiving either 16 mg once daily or 8 mg twice daily of poziotinib, measuring the drug's effectiveness through objective response rate and other secondary endpoints.
- Results showed a 39% overall response rate and a 73% disease control rate, with manageable side effects such as rash and stomatitis, indicating that poziotinib is a promising treatment for this specific group of NSCLC
Context: Patient-reported outcome measures (PROMs) should be used in athletic training and athletic therapy but are rarely incorporated in internships. Student-run clinics are common in other health professions and provide effective treatment and valuable learning environments. To our knowledge, no one has evaluated rehabilitation outcomes in patients treated by athletic therapy students (ATSs).
View Article and Find Full Text PDFPurpose: Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene ( or ) exon 20 occur in 2%-5% of non-small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib, a tyrosine kinase inhibitor, was evaluated in previously treated patients with NSCLC with exon 20 insertions.
Methods: ZENITH20, a multicenter, multicohort, open-label phase II study, evaluated poziotinib in patients with advanced or metastatic NSCLC.
Context: Athletes are often exposed to pain due to injury and competition. Using preliminary evidence, researchers have shown that cardiovascular measures could be an objective measure of pain, but the cardiovascular response can be influenced by psychological factors, such as catastrophizing.
Objective: To use a painful cold-pressor test (CPT) to measure the relationship among catastrophizing, pain, and cardiovascular variables in athletes.
Eflapegrastim (Rolontis) is a long-acting granulocyte colony-stimulating factor (G-CSF) with an IgG4 Fc fragment and short polyethylene glycol linker. Current G-CSF products are administered 24 hours after chemotherapy. The present study compares the duration of neutropenia (DN) with eflapegrastim or pegfilgrastim at 0, 2, 5, or 24 hours post chemotherapy.
View Article and Find Full Text PDF